title: [Simvastatin therapy and effect on hiperlipidemia and vascular status in nephrotic children with sustained dyslipidemia].
abstract: Dyslipidemia is common in nephrotic children and persistent lipid abnormalities are risk factor of late vascular complications. The aim of the study was evaluation of efficacy and safety of 12-months simvastatin therapy in nephrotic children with lipid profile abnormalities present despite clinical remission lasting for at least 8 weeks, including ultrasonographic assessment of carotid and femoral arteries.
  
  
  METHODS
  Overall 52 children (40 steroid-dependent and 12 steroid-resistant) were initially introduced to the study and 29 of them were treated with simvastatin. Normalisation of lipid profile was achieved in 19/29 (65.5%) and improvement in 9/29 (31%). Significant reduction in total cholesterol (p < 0.00001), LDL-C (p < 0.000003), VLDL- (p < 0.0123), oxy-LDL-C fractions (p < 0.0002) and triglycerides (TG) (p < 0.0005) serum concentration was achieved in non-proteinuric patients.
  
  
  RESULTS
  Analysis of the intima-media thickness (IMT) of the common carotid (c) and superficial femoral (f) arteries values revealed positive correlation between baseline cIMT and VLDL-C (p = 0.038) and TG concentration (p = 0.008), as well as positive correlation between fIMT and baseline creatinine (p = 0.04) and LDL-C serum concentration (p = 0.032) after simvastatine treatment. Number of children with significant vessels pathology (Z-score > 2.0) was small. Increased cIMT was seen at baseline in 4 patients and in 5 after simvastatin treatment, however average and Z-score values in children under simvastatin treatment have decreased. Increased fIMT values were seen at baseline in 2 and in one case after simvastatin treatment. Tolerance of simvastation was very good in all cases but one.
  
  
  CONCLUSIONS
  Simvastatin therapy was effective and safe in nephrotic non-proteinuric children with abnormal lipid profile. Fair estimation of impact of the 12-months simvastatin therapy on vascular status was not available due to limited number of children with significantly increased IMT at baseline.
authors.affiliation: Department of Nephrology, Kidney Transplantation and Hypertension, Children's Memorial Health Institute in Warsaw, Poland.
authors.forename: Joanna
authors.initials: J
authors.lastname: Ksiazek
authors.forename: Anna
authors.initials: A
authors.lastname: Niemirska
authors.forename: Maria
authors.initials: M
authors.lastname: Lipka
authors.forename: Aldona
authors.initials: A
authors.lastname: Wierzbicka
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Syczewska
authors.forename: Ryszard
authors.initials: R
authors.lastname: Grenda
mesh_terms: D000293:Adolescent; D002339:Carotid Arteries / Q000000981:diagnostic imaging; D002648:Child; D005260:Female; D005263:Femoral Artery / Q000000981:diagnostic imaging; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D009401:Nephrosis / Q000150:complications*; D019821:Simvastatin / Q000627:therapeutic use*; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D000960:Hypolipidemic Agents; D019821:Simvastatin